Investment8 Dec 2025, 10:57 am
Venus Remedies Completes AMR Licensing Milestones, Receives Final 11 Crore Payment from Cipla
AI Summary
Venus Remedies Ltd has completed all anticipated commercial milestones under a 2019 arrangement with Cipla Ltd for its novel AMR-focused anti-infective in the Indian territory. The patented product, developed by Venus Medicine Research Centre, has delivered therapeutic benefits to over one million patients. This AMR-targeted therapy has become an important option in hospital practice, reflecting a favourable safety profile in real-world use. Venus Remedies and VMRC remain committed to sustained innovation in AMR.
Key Highlights
- Venus Remedies has completed all AMR licensing milestones under a 2019 arrangement with Cipla
- The patented product has delivered therapeutic benefits to over one million patients
- The AMR-targeted therapy has become an important option in hospital practice
- The product has a favourable safety profile in real-world use
- Venus Remedies and VMRC remain committed to sustained innovation in AMR